| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5583141 | AZURITY | Heterocyclic compounds and their use as angiotensin antagonists |
Dec, 2013
(10 years ago) | |
| US7157584 | AZURITY | Benzimidazole derivative and use thereof |
May, 2025
(1 year, 25 days from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5958961 | AZURITY | Pharmaceutical composition for angiotensin II-mediated diseases |
Jun, 2014
(9 years ago) | |
| US7572920 | AZURITY | Benzimidazole derivative and use as a II receptor antagonist |
Jan, 2025
(8 months from now) | |
| US9066936 | AZURITY | Solid pharmaceutical composition comprising a benzimidazole-7-carboxylate derivative and a pH control agent |
Mar, 2028
(3 years from now) | |
Edarbi is owned by Azurity.
Edarbi contains Azilsartan Kamedoxomil.
Edarbi has a total of 5 drug patents out of which 2 drug patents have expired.
Expired drug patents of Edarbi are:
- US5958961
- US5583141
Edarbi was authorised for market use on 25 February, 2011.
Edarbi is available in tablet;oral dosage forms.
Edarbi can be used as treatment of hypertension.
Drug patent challenges can be filed against Edarbi from 25 February, 2015.
The generics of Edarbi are possible to be released after 26 March, 2028.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Feb 25, 2016 |
Drugs and Companies using AZILSARTAN KAMEDOXOMIL ingredient
NCE-1 date: 25 February, 2015
Market Authorisation Date: 25 February, 2011
Treatment: Treatment of hypertension
Dosage: TABLET;ORAL
EDARBI family patents
